Birth defects in offspring of adult survivors of childhood acute lymphoblastic leukemia: A Childrens Cancer Group/National Institutes of Health report
โ Scribed by Lisa B. Kenney; H. Stacy Nicholson; Cynthia Brasseux; James L. Mills; Leslie L. Robison; Lonnie K. Zeltzer; Anna T. Meadows; Gregory H. Reaman; Julianne Byrne
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 682 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
BACKGROUND.
It is not known if therapy for acute lymphoblastic leukemia (ALL) during childhood increases the risk of birth defects in the offspring of adult survivors. The Childrens Cancer Group (CCG), in collaboration with the National Institutes of Health (NIH), conducted a retrospective cohort study of adults successfully treated for childhood ALL to determine if their offspring had an increased incidence of birth defects compared with the offspring of their sibling controls.
METHODS.
Study subjects were patients who had been enrolled on CCG ALL protocols, who were treated for ALL prior to age 20, who survived at least 2 years, and who were at least age 18. Survivors (N = 593) and sibling controls (N = 409) were interviewed by telephone.
RESULTS.
The mean age of survivors was 22.6 years; the mean age of controls was 25.2 years. Among survivors, 93 (15.7%) had given birth to or fathered a total of 140 live-born offspring, (mean age, 3.4 years), and 122 (29.8%) sibling controls had given birth to or fathered a total of 228 live-born offspring (mean age, 5.9 years). There was no difference in the rate of birth defects between offspring of survivors
๐ SIMILAR VOLUMES
## Background: The authors have determined the prognostic significance of cytogenetically detectable 12p abnormalities, which are frequent in children with acute lymphoblastic leukemia (all), in a large cohort of patients treated on risk-adjusted protocols of the children's cancer group (ccg). ##
The outcome of children with acute lymphoblastic leukemia (ALL) and bone marrow relapse has been unsatisfactory largely because of failure to prevent subsequent leukemia relapses. Ninety-six patients were enrolled and received vincristine, prednisone, L-asparaginase, and an anthracycline as reinduc
## BACKGROUND. Children with Philadelphia (Ph) chromosome positive ( ฯฉ ) acute lymphoblastic leukemia (ALL) represent a subgroup at very high risk for treatment failure. In this report, the authors assessed the outcome of Ph ฯฉ ALL in a large cohort of children treated on contemporary intensive che